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Abstract
Background: Focal nodular hyperplasia (FNH) is the second most common benign hepatic tumor and is very rarely
complicated by hemorrhage or rupture. Although thought to be extremely rare, there have been several reports of
hemorrhage caused by ruptured FNH. Herein, we report the case of a patient with ruptured FNH, who subsequently
developed hemorrhage during follow-up.
Case presentation: A 32-year-old man was admitted to our department for an asymptomatic hepatic tumor in
segments 4 and 5 (S4/5), which measured 8 cm in diameter and observed to project from the liver. Imaging
and pathologic examination of a biopsy specimen confirmed the diagnosis of FNH. Three years after the diagnosis, the
patient was readmitted to our hospital because of sudden onset of upper abdominal pain. Dynamic abdominal
computed tomography revealed ascites around the tumor with high-density areas that were considered to represent
hematoma caused by ruptured FNH. Transcatheter arterial embolization (TAE) was performed to stop the hemorrhage.
One month after TAE, S4/5 of the liver was resected; macroscopic findings revealed that a large part of the tumor
was composed of necrotic tissue and hematoma. Pathological examination using hematoxylin–eosin staining and
immunohistochemical examination indicated a final diagnosis of FNH rupture and hemorrhage.
Conclusion: Although a well-established diagnosis of FNH usually requires no treatment or surveillance, careful
examination remains necessary when the FNH is large and projects from the liver because of the possibility of
rupture and hemorrhage.
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Background
Focal nodular hyperplasia (FNH) is the second most com-
mon benign hepatic tumor after cavernous hemangioma
[1–3]. Although a large FNH is often associated with sig-
nificant symptoms, almost all tumors remain stable in size
and do not develop complications, such as hemorrhage
and rupture. Therefore, FNH usually requires no treat-
ment or surveillance if the diagnosis is well established
[4, 5]. However, hemorrhage caused by ruptured FNH
may develop [5–13], although such instances appear to
be extremely rare. Here, we reported the case of a patient
with ruptured FNH that caused hemorrhage during
follow-up.
Case presentation
A 32-year-old man was admitted to our department
because of a hepatic tumor. Although the patient was
asymptomatic, his previous medical history included
chronic alcohol consumption for the past 8 years. Dynamic
abdominal computed tomography (CT) scan revealed
an 8-cm mass that projected from segments 4–5 (S4/5) of
the liver. The tumor exhibited contrast enhancement,
mainly on the border, from the early phase until the late
phase. The tumor contained a low-density area that was
considered as a central stellate scar (Fig. 1a, b). Dynamic
abdominal magnetic resonance imaging (MRI) showed a
mass with contrast enhancement during the early phase
until the hepatobiliary phase (Fig. 1c, d). Pathologic exam-
ination of a percutaneous biopsy sample from the tumor
showed fibrous connective tissue and a bile ductule without
a normal portal vein (Fig. 2a, b). The tumor was diagnosed
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as FNH. The patient was advised regular follow-up with no
treatment.
Three years after diagnosis, he was readmitted to our
hospital because of sudden onset of upper abdominal pain
without any preceding traumatic events. His hemodynamic
status on admission was nearly stable, except for tachycardia
(117 beats per minute). Further physical examination re-
vealed a palpable induration with tenderness and peritoneal
signs on the epigastrium. Laboratory test results on ad-
mission revealed no anemia (hemoglobin, 15.7 g/dl, and
hematocrit, 45.2%) and an increased white blood cell
count (17,700 cells/μl). The serum levels of C-reactive pro-
tein (30.2 mg/dl), aspartate aminotransferase (256 U/l), and
alanine aminotransferase (491 U/l) were also elevated. Dy-
namic abdominal CT scan showed a small amount of
ascites around the tumor. Most of the tumor was observed
as a low-density area, but there were high-density areas,
which were considered as hematoma around the tumor
(Fig. 3a). These findings indicated that the abdominal pain
was due to a ruptured FNH.
Although extravasation was not obvious on dynamic
CT and the hemodynamic status of the patient was
almost stable, the possibility of continuous hemorrhage
could not be ruled out because of the presence of hematoma
around the tumor, severe abdominal pain, and tachycardia.
Although the tumor had been initially diagnosed as
FNH, we deemed that hepatic angiography was necessary
for reassessment and accurate diagnosis of the hepatic
lesion because of the extreme rarity of a ruptured FNH.
Hepatic angiography showed patent arterial branches of
Fig. 1 Diagnostic imaging findings upon first admission. Dynamic abdominal CT imaging reveals an 8-cm mass projecting from the liver. Contrast
enhancement is mainly on the border, and it is observed in the early phase (a) until the late phase (b). In the early phase, a low-density area in
the tumor is considered as a central stellate scar (arrow). Dynamic abdominal MRI shows contrast enhancement in the early phase (c) until the
hepatobiliary phase (d)
Fig. 2 Pathologic examination of a percutaneous liver biopsy sample. Fibrous connective tissue, including a bile ductule (b, arrow), and absence
of a normal portal vein in the specimen are shown. a Hematoxylin–eosin staining (×100) and b Azan staining (×200)
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the S4 and S5 without a spoke-wheel pattern, but with
extravasation.
Transcatheter arterial embolization (TAE) of the arterial
branches of S4 and S5 was performed to stop the bleeding
(Fig. 3b, c). One month after TAE, his condition improved
by conservative treatment and elective surgery was
performed. On laparotomy, a large S4/5 hepatic tumor
adherent to the omentum, minimal ascites, and an old
hematocele were observed. Partial resection of the S4/
5 was performed. Macroscopic findings of the surgical
specimen showed that most of the tumor was composed
of necrotic tissue and hematoma (Fig. 4a). Pathologic
examination of the hematoxylin–eosin-stained biopsy
sample showed no atypical cells, hepatocyte proliferation,
and expanded blood vessels. An area with normal portal
vein was not observed (Fig. 4b). Immunohistochemical
analyses revealed inactivation of β-catenin and no attenu-
ation of liver fatty acid-binding protein (Fig. 4c, d). The
expression of glutamine synthetase (GS) in the tumor
region demonstrated the so-called “map-like” pattern
(Fig. 4e). From these findings, a final diagnosis of ruptured
FNH was made. Postoperatively, the patient was stable
and has survived symptom free for 2 years.
Discussion
FNH accounts for approximately 8% of all primary
hepatic tumors, with an estimated prevalence of 0.9%
in the general population [2]. FNH occurs in all age
groups in both men and women, but it is more frequent
in women aged 20–50 years (i.e., in the reproductive age)
[14], especially in those using oral contraceptives [15, 16].
In fact, an association between female hormones, such as
estrogen or progesterone, and the occurrence and in-
creasing size of FNH have been suspected; however,
this remains to be established [17, 18]. Although the
etiology of FNH remains undefined, it may represent a
tissue-specific ischemic response to congenital vascular
anomalies [19]. Alternatively, this lesion may result
from an arteriovenous malformation exerting abnormal
pressure on the surrounding sinusoids and portal vein
branches [20]. An anomalous arterial supply in FNH
has been demonstrated by arteriography [21].
Most FNHs are incidentally discovered with few clinical
clues [3]. Only 20% of patients reported signs and symp-
toms secondary to a liver mass [1, 16, 21, 22]. The presence
of a central stellate scar in the tumor is a characteristic find-
ing on abdominal ultrasonography, CT, and MRI [14, 23].
Fig. 3 Diagnostic imaging findings at 3 years after initial admission. Dynamic abdominal CT shows minimal ascites around the tumor. Most of the
tumor is depicted as a low-density area with some high-density areas that indicate hematoma formation (a). Emergency arterial angiography is
performed (b, c). The tumor is stained (b, short arrow) from the arterial branches of S4 (b, long arrow) and S5 (c, arrow). Extravasation (c, short
arrow) from the arterial branch of S5 is observed, and TAE was performed
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Compared with abdominal gray-scale ultrasonography or
CT, MRI has a high diagnostic yield for FNH, with sensitiv-
ity of 68–70% and specificity of 98–100% [14, 24, 25]. Par-
ticularly, MRI with hepatobiliary-specific contrast agents,
such as gadoxetic acid and gadobenate dimeglumine, is very
useful in diagnosing FNH, and it has been reported to have
96–97% specificity and 96% positive predictive value
[25, 26]. In the hepatobiliary phase of gadoxetate disodium-
enhanced MRI (Gd-EOB-MRI), FNH usually appears as an
iso- or hyperintense lesion [27], compared with malignant
tumors and hepatocellular adenoma (HCA), majority of
which demonstrate hypointensity [28]. Similarly, contrast-
enhanced ultrasonography (CEUS) can contribute to
accurate diagnosis of FNH by real-time evaluation of
vascularization and detection of the characteristic spoke-
wheel pattern. FNH can present on CEUS as a hyper- or
isointense lesion in the Kupffer phase because of the pres-
ence of Kupffer cells; in addition, CEUS can differentiate
between benign and malignant focal hepatic lesions
[29–31]. In this present case, tumor was recognized in
the hepatobiliary phase of Gd-EOB-MRI as a hyperin-
tense mass that contained a low-density area, which
was a central stellate scar. However, we assessed that
an accurate diagnosis by pathologic examination of a
liver biopsy specimen should be performed because of
some atypical features, such as male gender and an
equivocal finding of a central scar. Although CEUS was
not performed in our present case, evaluation of real-time
dynamism and the Kupffer phase on CEUS should be con-
sidered for non-invasive diagnosis of FNH before biopsy.
Microscopically, FNH is a confluent mass of several
small nodules of benign-appearing hepatocytes, partially
or surrounded by fine bands of fibrous tissue containing
proliferating bile ductules and vessels. It lacks a capsule
and grows in an expansive manner to compress the adja-
cent hepatic parenchyma, which may exhibit a pattern of
sinusoidal congestion [32–34]. The value of immunohis-
tochemistry in diagnosis of FNH has been recently ex-
plored. GS is an enzyme involved in detoxification of
ammonia by combining it with glutamate to produce the
amino acid glutamine. In the normal liver, GS expression
is limited to a narrow rim of hepatocytes around the
central vein [35, 36]. This zonation is thought to be the
result of β-catenin activation in centrizonal hepatocytes,
which may be the result of Wnt signaling from the
central vein [35, 36]. In FNH, there is expansion of the
β-catenin-activated centrizonal region, which leads to
overexpression in a characteristic “geographic map-
like” pattern [37, 38], as in the present case. A small
subset of β-catenin-activated HCAs may present with
diffuse cytoplasmic expression of GS, but the map-like
pattern typical of FNH is not observed. GS can pro-
vide strong evidence to differentiate between FNH and
β-catenin-activated HCA [38, 39].
Several studies reported that FNH does not have an
aggressive or malignant course [4, 19, 22]. Therefore,
FNH usually requires no treatment or surveillance if the
diagnosis is well established. However, although extremely
rare, FNH associated with intraperitoneal hemorrhage has
been reported in ten cases, including the present case,
based on review of English literature since 1974 (Table 1)
[5–13]. All cases, except this patient, were women; fatal
hemorrhage occurred in one patient in late pregnancy
[13]. The maximum tumor diameter ranged from 1 to
10 cm (median, 7 cm). Among the cases in which the
location could be estimated, the tumors were located at
Fig. 4 Macroscopic and histopathologic findings of the surgical specimen. Grossly, most of the tumorous tissue is replaced by hemorrhage (a).
Hematoxylin–eosin staining shows the absence of atypical cells and normal portal vein area, but there are hepatocyte proliferation and expanded
blood vessels (b, ×40). Immunohistochemical analyses (c–e) show inactivation of β-catenin and no attenuation of the LFABP (c, β-catenin, ×40,
and d, LFABP, ×40). Glutamine synthetase in the tumor region presents as the so-called geographic map-like pattern (e, arrows ×40). LFABP, liver
fatty acid-binding protein
Kinoshita et al. Surgical Case Reports  (2017) 3:44 Page 4 of 6
or near the liver surface. Li et al. recommended surgical
resection over observation for large FNH (>5 cm), irre-
spective of the presence of symptoms, because surgery
was associated with less mortality and it can estimate the
possibility of rupture or hemorrhage [12]. Surgical resec-
tion was performed in nine patients because one patient
was diagnosed during autopsy [13]; in three patients, in-
cluding this patient, preoperative TAE was performed.
Spontaneous rupture occurs in 3–26% of hepatocellular
carcinoma (HCC) cases, and it is regarded as a life-
threatening condition [40–45]. Some studies reported that
TAE is effective in controlling bleeding from a ruptured
HCC in the acute phase [46–48]. Hsueh et al. reported that
the prognosis of a ruptured HCC after TAE was better than
that after conservative treatment and that TAE achieved
successful hemostasis in 99% of patients [49]. For patients
with ruptured FNH, TAE may be also effective in control-
ling bleeding in the acute phase. In the present case, ex-
travasation was revealed on hepatic angiography and TAE
was performed. Staged resection after TAE should be con-
sidered for selected patients based on the presentation of
repeated hemorrhage and extensive tumor necrosis, as ob-
served in the present case. TAE and staged resection should
be considered a standard treatment for ruptured FNH.
Conclusions
In conclusion, although majority of FNH cases are
asymptomatic and require no treatment, spontaneous
rupture may occur in some patients during the follow-
up period. Although ruptured FNH is extremely rare,
careful examination is necessary for a large FNH that
projects from the liver because of the risk of spontan-
eous rupture, which can present as sudden onset of
abdominal pain.
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